Blog Know Your Enemy: Accurate Identification of Microorganisms is the Key to Environmental Monitoring Jun 10, 2013 Compounding pharmacies often act more like drug manufacturers than pharmacies, and as such, ought to abide by the same rules to ensure the medicines they produce are safe and pure. A Look at the 3Rs Apr 01, 2013 Replacement, Reduction and Refinement–past and present Cutting-edge Preclinical QT Assessment Reduces Late-stage Drug Failures Mar 26, 2013 The clinical effects of drugs on cardiac repolarization and rhythm, particularly the induction of potentially fatal arrhythmias have been increasingly documented over the past two decades. Mission at Work: Mike Hession Feb 15, 2013 Inspiring stories profiling how Charles River employees and their families are benefiting from our work. NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy. Orphan Disease Market: Untapped Drug Development Opportunities Abound Dec 10, 2012 Orphan diseases used to be a lonely place in drug development. But with recent analyses showing high profitability potential, support from advocacy organizations, and new therapeutic approaches, companies are beginning to embrace rare diseases. Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines? Abandon the Amyloid Hypothesis? New Research Says Not So Fast Nov 26, 2012 After the recent failures of two Alzheimer’s drugs that target amyloid beta plaques, many have questioned the approach. But new data released in October shows promise. Photosafety Testing, Lighting the Way Forward Aug 08, 2012 Some drugs can cause adverse effects on the skin and eye when the person taking them is exposed to sunlight. Understanding that ability and controlling the risk versus therapeutic benefit is critical for drug development. Animal Models Shed Light on Cancer of the Brain Jul 30, 2012 Poorly understood pediatric cancers, such as medulloblastoma, are investigated with experimental animal models, elucidating the genes and pathways driving the disease.
Know Your Enemy: Accurate Identification of Microorganisms is the Key to Environmental Monitoring Jun 10, 2013 Compounding pharmacies often act more like drug manufacturers than pharmacies, and as such, ought to abide by the same rules to ensure the medicines they produce are safe and pure.
Cutting-edge Preclinical QT Assessment Reduces Late-stage Drug Failures Mar 26, 2013 The clinical effects of drugs on cardiac repolarization and rhythm, particularly the induction of potentially fatal arrhythmias have been increasingly documented over the past two decades.
Mission at Work: Mike Hession Feb 15, 2013 Inspiring stories profiling how Charles River employees and their families are benefiting from our work.
NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy.
Orphan Disease Market: Untapped Drug Development Opportunities Abound Dec 10, 2012 Orphan diseases used to be a lonely place in drug development. But with recent analyses showing high profitability potential, support from advocacy organizations, and new therapeutic approaches, companies are beginning to embrace rare diseases.
Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines?
Abandon the Amyloid Hypothesis? New Research Says Not So Fast Nov 26, 2012 After the recent failures of two Alzheimer’s drugs that target amyloid beta plaques, many have questioned the approach. But new data released in October shows promise.
Photosafety Testing, Lighting the Way Forward Aug 08, 2012 Some drugs can cause adverse effects on the skin and eye when the person taking them is exposed to sunlight. Understanding that ability and controlling the risk versus therapeutic benefit is critical for drug development.
Animal Models Shed Light on Cancer of the Brain Jul 30, 2012 Poorly understood pediatric cancers, such as medulloblastoma, are investigated with experimental animal models, elucidating the genes and pathways driving the disease.
